Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Ketone Monitoring in T1D Using Empagliflozin
NCT06753994Phase 1Completed
- Sponsor
- McGill University
- Start
- Dec 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in type 1 diabetes mellitus (T1D), sponsored by McGill University. Primary endpoint: Number of ketone elevation events lasting >1 hour at 17 weeks. Started Dec 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06753994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06753994.